真实世界中一线和二线抗血管生成疗法在肾细胞癌中的疗效：一项基于英国人群的分析。

Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

机构信息

Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.

University of Manchester, Manchester, UK.

出版信息

Future Oncol. 2024;20(33):2547-2558. doi: 10.1080/14796694.2024.2385882. Epub 2024 Oct 9.

Renal cell carcinoma (RCC) is the seventh commonest cancer in the UK, where first-line (1L) sunitinib and second-line (2L) axitinib are treatment options. Retrospective, non-interventional data from the Christie NHS Foundation Trust (Manchester, UK). The primary end point was median progression-free survival (mPFS). For 1L sunitinib (n = 622) and 2L axitinib (n = 121), mPFS (95% CI) was 8.4 (7.6, 9.9) and 6.2 (4.9, 9.3) months, respectively. In 1L, Karnofsky performance status, lactate dehydrogenase (LDH), neutrophils, hemoglobin, time from diagnosis to treatment and age were predictors ( < 0.05) of PFS. In 2L, LDH and platelets were predictors of PFS ( < 0.05). Sunitinib and axitinib were effective treatments for RCC. PFS predictors varied between 1L and 2L; LDH was a predictor for both. NCT04033991 (ClinicalTrials.gov).

肾细胞癌（RCC）是英国第七大常见癌症，舒尼替尼（sunitinib）作为一线治疗（1L），阿昔替尼（axitinib）作为二线治疗（2L）。该研究为克里斯蒂 NHS 基金会信托（英国曼彻斯特）的回顾性、非干预性数据。主要终点为中位无进展生存期（mPFS）。对于 1L 舒尼替尼（n=622）和 2L 阿昔替尼（n=121），mPFS（95%CI）分别为 8.4（7.6，9.9）和 6.2（4.9，9.3）个月。在 1L 中，卡氏功能状态评分、乳酸脱氢酶（LDH）、中性粒细胞、血红蛋白、从诊断到治疗的时间和年龄是 PFS 的预测因素（<0.05）。在 2L 中，LDH 和血小板是 PFS 的预测因素（<0.05）。舒尼替尼和阿昔替尼是治疗 RCC 的有效药物。1L 和 2L 之间的 PFS 预测因素不同；LDH 是两者的共同预测因素。NCT04033991（ClinicalTrials.gov）。